aTyr Pharma Secures $76,000,000 Series E Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=0ea9fa1e-2d6d-4fe5-a3af-9c6c3a011f8a - Date
4/1/2015 - Company Name
aTyr Pharma - Mailing Address
3565 General Atomics Court San Diego, CA 92121 USA - Company Description
We have developed proprietary methods for discovering Physiocrines, extracellular proteins that are derived from the tRNA synthetase family of enzymes, and which were predominantly overlooked by other genomic and secretome discovery efforts. - Website
http://www.atyrpharma.com - Transaction Type
Venture Equity - Transaction Amount
$76,000,000 - Transaction Round
Series E - Proceeds Purposes
The Company plans to use the proceeds to further develop its pipeline and advance its lead program through clinical trials, including an ongoing Phase 1b/2 trial of Resolaris, an investigational new drug representing aTyr’s first Physiocrine-based product candidate in the clinic. - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
